Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H9Cl2NO2S |
Molecular Weight | 302.176 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CSC=C1NC2=C(Cl)C=CC=C2Cl
InChI
InChIKey=AELILMBZWCGOSB-UHFFFAOYSA-N
InChI=1S/C12H9Cl2NO2S/c13-8-2-1-3-9(14)12(8)15-10-6-18-5-7(10)4-11(16)17/h1-3,5-6,15H,4H2,(H,16,17)
Molecular Formula | C12H9Cl2NO2S |
Molecular Weight | 302.176 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.in-farmacia.it/telzenac-fl-50ml.html | http://adisinsight.springer.com/drugs/800003785 | https://www.ncbi.nlm.nih.gov/pubmed/18674517
Curator's Comment: description was created based on several sources, including:
http://www.in-farmacia.it/telzenac-fl-50ml.html | http://adisinsight.springer.com/drugs/800003785 | https://www.ncbi.nlm.nih.gov/pubmed/18674517
Eltenac is a compound with a structural similarity to diclofenac with one benzol ring substituted by a tiophene ring. This modification has been shown to improve the absorption after topical application. Eltenac is an inhibitor of both cyclo-oxygenase-1 and -2. Eltenac had been in phase II clinical trial for the treatment of osteoarthritis of the knee. Eltenac is used in the alleviation of inflammation associated with musculoskeletal disorders and control of post-operative swelling, oedema and endotoxaemia in horses. The local skin reactions reported in humans were erythema, eczema, itching, rash and dry skin.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 |
0.03 µM [IC50] | ||
Target ID: CHEMBL230 |
0.03 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Telzenac Approved UseFor use in the alleviation of inflammation associated with musculoskeletal disorders and control of post-operative swelling, oedema and endotoxaemia in horses. |
|||
Preventing | Telzenac Approved UseFor use in the alleviation of inflammation associated with musculoskeletal disorders and control of post-operative swelling, oedema and endotoxaemia in horses. |
PubMed
Title | Date | PubMed |
---|---|---|
Eltenac, a new anti-inflammatory and analgesic drug for horses: clinical aspects. | 1991 Jun |
|
Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. | 1997 |
|
Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. | 2001 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.in-farmacia.it/telzenac-fl-50ml.html
Horses: 0.5 mg/kg (1 ml/100 kg) once daily for a period not exceeding 5 days.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:56:34 GMT 2023
by
admin
on
Fri Dec 15 15:56:34 GMT 2023
|
Record UNII |
A153L3JA99
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5723
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
100000080731
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
A153L3JA99
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
51717
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
C071200
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
DTXSID30223184
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
SUB06495MIG
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
72895-88-6
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104561
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY | |||
|
C77358
Created by
admin on Fri Dec 15 15:56:34 GMT 2023 , Edited by admin on Fri Dec 15 15:56:34 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |